Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Kythera Biopharmaceuticals has received $37m funding under Series D financing to conduct US Phase III trial to evaluate its investigational injectable drug, ATX-101 for the reduction of submental fat.
Subscribe to our email newsletter
The company has started the European Phase III trials of ATX-101 in 2010 in collaboration with Intendis, Bayer HealthCare’s dermatology unit, which has licensed rights to ATX-101 outside of the US and Canada.
The funding has been granted by its investors, Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco, Partner Funds management (PFM), Invus Financial Advisors, BBT Capital Management/Apothecary Capital, and Altitude Life Science Ventures.